{"id":8165,"date":"2025-07-29T11:37:09","date_gmt":"2025-07-29T08:37:09","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=8165"},"modified":"2025-07-29T11:37:09","modified_gmt":"2025-07-29T08:37:09","slug":"scientific-summary-new-drug-for-afib-fails-in-a-first-in-human-clinical-pilot-trial-2","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/scientific-summary-new-drug-for-afib-fails-in-a-first-in-human-clinical-pilot-trial-2\/","title":{"rendered":"Scientific Summary: New Drug for AFib Fails in A First-in-Human Clinical Pilot Trial"},"content":{"rendered":"<div>Scientific Summary: New Drug for AFib Fails in A First-in-Human Clinical Pilot Trial<\/div>\n<div><\/div>\n<div>Source: Circulation<\/div>\n<div>Published 25 July 2025<\/div>\n<div><\/div>\n<div><span> 1. Background:<\/span><\/div>\n<div><span> \u2022 Atrial fibrillation (AFib) is the most common arrhythmia in adults.<\/span><\/div>\n<div><span> \u2022 Inflammation and oxidative stress are suspected contributors to AFib.<\/span><\/div>\n<div><span> \u2022 Researchers hypothesized that reducing inflammation may lower AFib risk.<\/span><\/div>\n<div><span> 2. Rationale for the Study:<\/span><\/div>\n<div><span> \u2022 AFib is strongly associated with obesity, metabolic syndrome, hypertension, and aging\u2014all of which are known to promote chronic inflammation and oxidative stress.<\/span><\/div>\n<div><span> \u2022 These shared mechanisms suggest a potential final common pathway in AFib development.<\/span><\/div>\n<div><span> \u2022 The trial aimed to test whether targeting inflammation using the compound 2-HOBA, which scavenges isolevuglandins (toxic oxidative byproducts), could reduce AFib recurrence following catheter ablation.<\/span><\/div>\n<div><span> 3. Study Design:<\/span><\/div>\n<div><span> \u2022 First-in-human, placebo-controlled trial.<\/span><\/div>\n<div><span> \u2022 Participants: Nearly 100 white patients (median age: 63, 64.6% male) post-AFib ablation.<\/span><\/div>\n<div><span> \u2022 Two groups: 43 patients received 2-HOBA, 39 received placebo.<\/span><\/div>\n<div><span> 4. Key Findings:<\/span><\/div>\n<div><span> \u2022 28-day AFib recurrence:<\/span><\/div>\n<div><span> \u2022 60.5% in the 2-HOBA group vs 35.9% in placebo group.<\/span><\/div>\n<div><span> \u2022 12-month follow-up:<\/span><\/div>\n<div><span> \u2022 No significant difference in event-free survival.<\/span><\/div>\n<div><span> \u2022 2-HOBA increased, rather than decreased, early AFib recurrence risk.<\/span><\/div>\n<div><span> 5. Conclusions:<\/span><\/div>\n<div><span> \u2022 The trial results contradicted the hypothesis: 2-HOBA worsened outcomes.<\/span><\/div>\n<div><span> \u2022 Even after adjusting for age, sex, BMI, ablation type, and monitoring hours, the negative effect remained.<\/span><\/div>\n<div><span> \u2022 The study showed no statistical anomaly\u2014results were consistent and robust.<\/span><\/div>\n<div><span> 6. Broader Context:<\/span><\/div>\n<div><span> \u2022 Other anti-inflammatory or antioxidant strategies for AFib (e.g., Vitamin C, colchicine, corticosteroids, omega-3) have also shown limited or inconsistent benefits.<\/span><\/div>\n<div><span> \u2022 Researchers call for more effective and targeted strategies in AFib prevention.<\/span><\/div>\n<div><\/div>\n<div><a href=\"https:\/\/doi.org\/10.1161\/CIRCEP.124.013378\">https:\/\/doi.org\/10.1161\/CIRCEP.124.013378<\/a><\/div>\n<div><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Scientific Summary: New Drug for AFib Fails in A First-in-Human Clinical Pilot Trial Source: Circulation Published 25 July 2025 1. Background: \u2022 Atrial fibrillation (AFib) is the most common arrhythmia in adults. \u2022 Inflammation and oxidative stress are suspected contributors to AFib. \u2022 Researchers hypothesized that reducing inflammation may lower AFib risk. 2. Rationale for [&hellip;]<\/p>\n","protected":false},"author":145,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-8165","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8165","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/145"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=8165"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8165\/revisions"}],"predecessor-version":[{"id":8166,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8165\/revisions\/8166"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=8165"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=8165"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=8165"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}